Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The safety, tolerability, pharmacokinetics and pharmacodynamics/efficacy profiles of two different doses of GSK233705 will be compared with 2 active comparators and placebo, all medication delivered via dry powder inhaler.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Salmeterol Xinafoate; Tiotropium Bromide

Criteria

Inclusion criteria:

• females of non-childbearing potential or postmenopausal;

• history of COPD as defined by ATS/ERS criteria;

• moderate COPD responsive to ipratropium and salbutamol;

• current smoker or ex-smoker.

Exclusion criteria:

• no instable COPD; max 1000 mcg inhaled steroids per day; no B-blockers